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the Literature
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Leptomeningeal metastases (LM) are found in approximately 3.8% of non-small cell lung 
cancer cases with an increased incidence in adenocarcinoma, and approximately one-
third of patients will present with concomitant brain metastases. We report the case of a 
50-year-old male patient with stage IV exon 19-del-EGFR mutant lung adenocarcinoma 
who progressed on second-generation TKI therapy with manifestation of symptomatic 
simultaneous diffuse brain and LM. Whole-brain radiotherapy with concurrent afatinib 
resulted in an almost complete regression of neurological symptoms as well as good, 
durable radiological response. Furthermore, treatment was well tolerated with no rele-
vant adverse effects.
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INtRoDUCtIoN
Leptomeningeal metastases (LM) represent the infiltration of the leptomeninges by malig-
nant cells (1) and are a readily increasing complication in cancer patients. LM are found in 
approximately 5% of patients with malignant tumors (1), and in non-small cell lung cancer 
(NSCLC), the incidence is approximately 3.8% with an increased incidence in adenocarcinoma, 
and roughly one-third of patients will present with concomitant brain metastases (BM) (2). The 
incidence is steadily increasing due to improvement in diagnostic tools such as neuroimag-
ing methods as well as availability of improved treatments, consecutively leading to improved 
survival. However, general prognosis remains poor in the order of 2–4 months (3–7). Currently, 
no standard treatment exists (8). Occurrence of LM under prolonged tyrosine-kinase inhibitor 
(TKI) therapy has been previously described (9).
Afatinib is a second-generation irreversible covalent inhibitor of the epidermal growth fac-
tor receptor (EGFR) tyrosine kinases including ErbB-2 (HER2) and ErbB-4. Subgroup analysis 
from LUX-LUNG 3 and LUX-LUNG 6 studies demonstrated a significant overall survival benefit 
for afatinib compared to chemotherapy in UICC stage IIIB/IV lung adenocarcinoma patients 
with 19del-EGFR mutation (10). Consecutively, in a combined post hoc analysis of both studies, 
progression free survival was significantly improved with afatinib vs. with chemotherapy in 
patients with BM (8.2 vs. 5.4 months; HR, 0.50; p = 0.0297) (11). There is a paucity of literature 
FIGURe 1 | axial contrast-enhanced 3D-Fast spIN eCHo spectral presaturation with inversion recovery [left: pre-whole-brain radiotherapy (WBRt); 
right: 9-month follow-up]: note decrease in intraparenchymal brain metastases and leptomeningeal enhancement pre- vs. post-WBRt. In addition, 
note consecutive enlargement of the lateral ventricles on 9-month follow-up scan.
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on concurrent radiotherapy and second-generation TKIs. In 
2014, Atmaca et  al. published a case report of a patient who 
received concomitant radiotherapy to the mediastinum and 
primary lung tumor with afatinib. The therapy resulted in 
partial remission in the irradiated sites without any relevant 
treatment-associated adverse effects (12). In addition, Li et al. 
reported in a case series on a 52-year-old male patient with BM 
from an L858R mutant adenocarcinoma of the lung. Whole-
brain radiotherapy (WBRT) was delivered to a total dose of 
30.0 Gy in 10 fractions, and afatinib was administered concur-
rently. Follow-up magnetic resonance imaging (MRI) showed 
regression of BM (13).
Case
The case of a 50-year-old male never smoker with stage IV 
Exon 19-del-EGFR mutant, ALK- and ROS-1-negative lung 
adenocarcinoma diagnosed in April 2015 was presented at the 
multidisciplinary tumor board. At initial diagnosis, the patient 
presented with malignant pleural effusion and FDG-avid dif-
fuse bone metastasis on 18F-FDG/PET-CT (positron emission 
tomography with 2-deoxy-2-[fluorine-18]fluoro-d-glucose inte-
grated with computed tomography). Due to Exon-19-deletion, 
afatinib 40 mg/day was prescribed. Follow-up imaging showed 
good extracranial remission. Approximately 12 months later, the 
patient presented with cephalalgia, seizures, impaired vision, and 
hypesthesia. Gadolinium-enhanced multiplanar MRI of the brain 
and spine showed isolated intraparenchymal and leptomeningeal 
carcinomatosis of the brain; the findings were conclusive for 
leptomeningeal spread (see Figures  1–3). Analysis of the cer-
ebrospinal fluid (CSF) confirmed the findings. The patient was 
started on oral dexamethasone. 18F-FDG-PET/CT confirmed no 
signs of extracranial tumor progression. The patient underwent 
WBRT with concurrent afatinib due to fear of extracranial tumor 
progression in the case afatinib was discontinued. WBRT was 
applied with 6 MV photon beams once daily; fourteen fractions 
to a total dose of 35.0  Gy and was well tolerated without any 
severe cutaneous adverse effects. Three-month follow-up MRI 
and 18F-FDG-PET/CT showed significant regression of intrac-
ranial disease as well as stable extracranial disease. Furthermore, 
the patient noted an almost complete regression of the above-
mentioned neurological symptoms. Approximately nine months 
following WBRT (see Figures  1–3), contrast-enhanced MRI 
of the brain showed sustained durable response in the absence 
of any severe neurological side effects. Furthermore, follow-up 
18F-FDG/PET-CT showed stable extracranial disease with mul-
tiple FDG non-avid sclerotic bone lesions as a sign of treatment 
response to afatinib. In addition, although there were no signs of 
tumor progression on the follow-up scans, after discussion at the 
multidisciplinary tumor board, precautionary further analysis of 
the CSF extracted at initial diagnosis of cranial metastases for 
acquired secondary T790M mutation was recommended.
DIsCUssIoN
Based on the National Comprehensive Cancer Network guide-
lines, WBRT is a mainstay in the treatment of BM. However, its 
role in the treatment of LM is yet to be clearly defined. Morris 
et al. demonstrated in a retrospective study on LM from NSCLC 
poor survival. In the study, survival was not improved by WBRT 
(14). In contrast, Soon et al. showed in a systematic review and 
meta-analysis that there was some evidence that upfront cranial 
radiotherapy might improve intracranial disease and survival 
outcomes compared with TKI alone in patients with EGFR 
mutant NSCLC (15). A recently published study by Jiang et al. 
demonstrated no overall survival benefit when first-generation 
TKIs combined with WBRT vs. TKIs alone were administered 
(16). Hoffknecht et al. showed that patients pretreated with first-
generation TKI and new intracranial progression could benefit 
from treatment conversion to afatinib (17).
In the present case, simultaneous intraparenchymal brain 
and LM arose during afatinib therapy despite extracranial tumor 
control, which can be partially attributed to EGFR mutation het-
erogeneity (18). There has been no study focusing on the efficacy 
of WBRT combined with afatinib in LM, but clinical studies on 
BM have shown that WBRT could increase the permeability of 
FIGURe 3 | sagittal contrast-enhanced 3D-Fast spIN eCHo spectral presaturation with inversion recovery [left: pre-whole-brain radiotherapy 
(WBRt); right: 9-month follow-up]: note decrease in intraparenchymal brain metastases enhancement pre- vs. post-WBRt. In addition, note 
enlargement of the ventricles on 9-month follow-up scan.
FIGURe 2 | Coronal contrast-enhanced t1-weighted magnetic resonance imaging [left: pre-whole-brain radiotherapy (WBRt); right: 9-month 
follow-up]: note decrease in leptomeningeal enhancement pre- vs. post-WBRt. In addition, note enlargement of the lateral ventricles on 9-month follow-up 
scan.
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TKI into the CSF (19, 20); hence, in this case, response may also 
be partially attributed to this phenomenon. In the present case, 
concomitant afatinib with WBRT was feasible with achievement 
of rash palliation of symptoms and good, durable radiological 
response in an Exon19-del EGFR-mutant lung adenocarcinoma 
patient who progressed during TKI therapy with the manifesta-
tion of simultaneous brain and LM. Remarkably, WBRT in 
combination with afatinib resulted in sustained tumor control 
going on 9 months following treatment at a stage of disease with 
dismal prognosis.
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